The relation of circulating YKL-40 to levels and decline of lung function in adult life

Respiratory Medicine

Volumn 107, Issue 12, 2013, Pages 1923-1930

  Guerra, Stefano ^a,b,c,d   Halonen, Marilyn ^a   Sherrill, Duane L ^a,e   Venker, Claire ^a,e   Spangenberg, Amber ^a   Carsin, Anne Elie ^b,c,d   Tarès, Lluïsa ^b,c,d   Lavi, Iris ^b,c,d   Barreiro, Esther ^c,f   Martínez Moratalla, Jesús ^g   Urrutia, Isabel ^h   Sunyer, Jordi ^b,c,d,f   Antó, Josep M ^b,c,d,f   Martinez, Fernando D ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITAT POMPEU FABRA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^h HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Lung function; Smoking; YKL 40

Indexed keywords

GLYCOPROTEIN; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; ATOPY; CORRELATION COEFFICIENT; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SMOKING;

LUNG FUNCTION; SMOKING; YKL-40;

ADIPOKINES; ADULT; AGED; ASTHMA; EPIDEMIOLOGIC METHODS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LECTINS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; VITAL CAPACITY; YOUNG ADULT;

EID: 84890314252     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.07.013     Document Type: Article

References (30)

1. D.R. Taylor Using biomarkers in the assessment of airways disease J Allergy Clin Immunol 128 5 2011 927 934 [quiz 35-6]
2. F.J. Martinez, J.F. Donohue, and S.I. Rennard The future of chronic obstructive pulmonary disease treatment - difficulties of and barriers to drug development Lancet 378 9795 2011 1027 1037
3. C.G. Lee, C.A. Da Silva, C.S. Dela Cruz, F. Ahangari, B. Ma, and M.J. Kang Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury Annu Rev Physiol 73 2011 479 501
4. G.L. Chupp, C.G. Lee, N. Jarjour, Y.M. Shim, C.T. Holm, and S. He A chitinase-like protein in the lung and circulation of patients with severe asthma N Engl J Med 357 20 2007 2016 2027
5. C. Ober, Z. Tan, Y. Sun, J.D. Possick, L. Pan, and R. Nicolae Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function N Engl J Med 358 16 2008 1682 1691
6. H. Tang, Z. Fang, Y. Sun, B. Li, Z. Shi, and J. Chen YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E Eur Respir J 35 4 2010 757 760
7. D.L. Goldman, X. Li, K. Tsirilakis, C. Andrade, A. Casadevall, and A.G. Vicencio Increased chitinase expression and fungal-specific antibodies in the bronchoalveolar lavage fluid of asthmatic children Clin Exp Allergy 42 4 2012 523 530
8. K. Specjalski, and E. Jassem YKL-40 protein is a marker of asthma J Asthma 48 8 2011 767 772
9. K. Otsuka, H. Matsumoto, A. Niimi, S. Muro, I. Ito, and T. Takeda Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease Respiration 83 6 2012 507 519
10. S. Letuve, A. Kozhich, N. Arouche, M. Grandsaigne, J. Reed, and M.C. Dombret YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages J Immunol 181 7 2008 5167 5173
11. H. Matsuura, D. Hartl, M.J. Kang, C.S. Dela Cruz, B. Koller, and G.L. Chupp Role of breast regression protein-39 in the pathogenesis of cigarette smoke-induced inflammation and emphysema Am J Respir Cell Mol Biol 44 6 2011 777 786
12. Y. Sakazaki, T. Hoshino, S. Takei, M. Sawada, H. Oda, and S. Takenaka Overexpression of chitinase 3-like 1/YKL-40 in lung-specific IL-18-transgenic mice, smokers and COPD PLoS One 6 9 2011 e24177
13. M.D. Lebowitz, R.J. Knudson, and B. Burrows Tucson epidemiologic study of obstructive lung diseases. I: Methodology and prevalence of disease Am J Epidemiol 102 2 1975 137 152
14. R.J. Knudson, R.C. Slatin, M.D. Lebowitz, and B. Burrows The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age Am Rev Respir Dis 113 5 1976 587 600
15. The European Community Respiratory Health Survey II Eur Respir J 20 5 2002 1071 1079
16. R.J. Knudson, M.D. Lebowitz, C.J. Holberg, and B. Burrows Changes in the normal maximal expiratory flow-volume curve with growth and aging Am Rev Respir Dis 127 6 1983 725 734
17. J.L. Hankinson, J.R. Odencrantz, and K.B. Fedan Spirometric reference values from a sample of the general U.S. population Am J Respir Crit Care Med 159 1 1999 179 187
18. H. Brown, and R. Prescott Applied mixed models in medicine 2001 John Wiley & Sons, LTD Chichester, UK
19. P.N. Lee, and J.S. Fry Systematic review of the evidence relating FEV1 decline to giving up smoking BMC Med 8 2010 84
20. J.M. Anto, J. Sunyer, X. Basagana, R. Garcia-Esteban, I. Cerveri, and R. de Marco Risk factors of new-onset asthma in adults: a population-based international cohort study Allergy 65 8 2010 1021 1030
21. J.K. Nikota, F.M. Botelho, C.M. Bauer, M. Jordana, A.J. Coyle, and A.A. Humbles Differential expression and function of breast regression protein 39 (BRP-39) in murine models of subacute cigarette smoke exposure and allergic airway inflammation Respir Res 12 2011 39
22. C.G. Lee, D. Hartl, G.R. Lee, B. Koller, H. Matsuura, and C.A. Da Silva Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis J Exp Med 206 5 2009 1149 1166
23. I. Bara, A. Ozier, J.M. Tunon de Lara, R. Marthan, and P. Berger Pathophysiology of bronchial smooth muscle remodelling in asthma Eur Respir J 36 5 2010 1174 1184
24. I. Bara, A. Ozier, P.O. Girodet, G. Carvalho, J. Cattiaux, and H. Begueret Role of YKL-40 in bronchial smooth muscle remodeling in asthma Am J Respir Crit Care Med 185 7 2012 715 722
25. J.S. Johansen, S.E. Bojesen, A. Tybjaerg-Hansen, A.K. Mylin, P.A. Price, and B.G. Nordestgaard Plasma YKL-40 and total and disease-specific mortality in the general population Clin Chem 56 10 2010 1580 1591
26. J.S. Johansen, A.N. Pedersen, M. Schroll, T. Jorgensen, B.K. Pedersen, and H. Bruunsgaard High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality Clin Exp Immunol 151 2 2008 260 266
27. C.N. Rathcke, I. Raymond, C. Kistorp, P. Hildebrandt, J. Faber, and H. Vestergaard Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population Int J Cardiol 143 1 2010 35 42
28. P.J. Barnes, and B.R. Celli Systemic manifestations and comorbidities of COPD Eur Respir J 33 5 2009 1165 1185
29. Y. Nussbaumer-Ochsner, and K.F. Rabe Systemic manifestations of COPD Chest 139 1 2011 165 173
30. J.S. Johansen, T. Lottenburger, H.J. Nielsen, J.E. Jensen, M.N. Svendsen, and G. Kollerup Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects Cancer Epidemiol Biomarkers Prev 17 10 2008 2603 2608